title: ALOX5 promoter genotype and response to montelukast in moderate persistent asthma.
abstract: BACKGROUND
  It was hypothesized that asthmatic patients with mutant alleles in the leukotriene pathway should not respond to leukotriene receptor antagonists and the concept of a tailored treatment is increasingly supported.
  
  
  METHODS
  Sixty-one patients (mean age 24.9 years, range 14-52) with moderate persistent asthma were clinical and immunological assess prior and after a 6-month treatment with montelukast. Tandem repeat polymorphisms were genotyped in the promoter (-147 to -176) of 5-lipoxygenase gene (ALOX5).
  
  
  RESULTS
  Thirty-two patients (52.5%) were homozygous for the five repeats allele; 17 (27.9%) were heterozygous (4/5 repeats) and 12 (19.7%) were homozygous for 4/4 repeats. After the montelukast treatment decrease number of asthma exacerbations, improvement of FEV(1) and decreased use of beta(2) agonists was observed in patients with 5/5 or 4/5 repeats. Conversely, the patients with 4/4 repeats genotype did not modify these data after treatment.
  
  
  CONCLUSIONS
  It was confirmed that ALOX5 promoter polymorphisms have a clear influence in montelukast response in atopic moderate persistent asthma patients. The genetic study could identify those patients most likely to respond to montelukast.
authors.affiliation: Institute of Biology and Molecular Genetics (IBGM/CSIC), University of Valladolid, Valladolid, Spain. juangose.telleria@uva.es <juangose.telleria@uva.es>
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Telleria
authors.forename: Alfredo
authors.initials: A
authors.lastname: Blanco-Quiros
authors.forename: David
authors.initials: D
authors.lastname: Varillas
authors.forename: Alicia
authors.initials: A
authors.lastname: Armentia
authors.forename: Isabel
authors.initials: I
authors.lastname: Fernandez-Carvajal
authors.forename: M
authors.initials: M
authors.lastname: Jesus Alonso
authors.forename: Ignacio
authors.initials: I
authors.lastname: Diez
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics*; D001249:Asthma / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D003521:Cyclopropanes; D005260:Female; D005541:Forced Expiratory Volume; D005838:Genotype; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011804:Quinolines / Q000627:therapeutic use*; D017678:Sex Distribution; D013440:Sulfides; D020080:Tandem Repeat Sequences / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D007073:Immunoglobulin E; D001094:Arachidonate 5-Lipoxygenase; C093875:montelukast